Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives $27.36 Consensus Target Price from Analysts

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have earned a consensus rating of “Hold” from the thirteen brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $27.36.

Several research analysts have issued reports on DCPH shares. HC Wainwright reduced their price objective on Deciphera Pharmaceuticals from $25.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, December 1st. downgraded Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $72.00 to $12.00 in a report on Monday, November 8th. SVB Leerink reissued a “buy” rating and issued a $70.00 price target on shares of Deciphera Pharmaceuticals in a research note on Monday, November 15th. JMP Securities cut their price target on Deciphera Pharmaceuticals from $70.00 to $64.00 and set a “market outperform” rating on the stock in a research note on Friday, November 5th. Finally, Jonestrading reissued a “sell” rating on shares of Deciphera Pharmaceuticals in a research note on Monday, November 22nd.

NASDAQ:DCPH traded down $0.02 during trading hours on Friday, hitting $8.39. 21,391 shares of the stock were exchanged, compared to its average volume of 2,429,650. The company’s 50 day moving average is $9.14 and its two-hundred day moving average is $24.39. Deciphera Pharmaceuticals has a twelve month low of $7.63 and a twelve month high of $52.67.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings data on Tuesday, November 2nd. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.29) by ($0.08). Deciphera Pharmaceuticals had a negative return on equity of 58.56% and a negative net margin of 300.00%. The firm had revenue of $23.22 million for the quarter, compared to analyst estimates of $23.73 million. During the same period in the prior year, the company posted ($1.13) EPS. On average, equities analysts predict that Deciphera Pharmaceuticals will post -5.14 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the business. Weiss Multi Strategy Advisers LLC increased its holdings in Deciphera Pharmaceuticals by 3.7% during the 2nd quarter. Weiss Multi Strategy Advisers LLC now owns 10,480 shares of the company’s stock worth $384,000 after purchasing an additional 374 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Deciphera Pharmaceuticals by 1.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,681 shares of the company’s stock worth $830,000 after purchasing an additional 401 shares in the last quarter. Lazard Asset Management LLC increased its holdings in Deciphera Pharmaceuticals by 69.7% during the 2nd quarter. Lazard Asset Management LLC now owns 1,739 shares of the company’s stock worth $63,000 after purchasing an additional 714 shares in the last quarter. Macquarie Group Ltd. increased its holdings in Deciphera Pharmaceuticals by 90.8% during the 2nd quarter. Macquarie Group Ltd. now owns 2,005 shares of the company’s stock worth $73,000 after purchasing an additional 954 shares in the last quarter. Finally, Cohanzick Management LLC increased its holdings in Deciphera Pharmaceuticals by 25.0% during the 2nd quarter. Cohanzick Management LLC now owns 5,000 shares of the company’s stock worth $183,000 after purchasing an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 78.98% of the company’s stock.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors.

Read More: What sectors are represented in the Hang Seng index?

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.